GLP-1 Inhibitors

Summary

---

Down to Business English – Episode Summary

Episode Title: GLP-1 Inhibitors
Date: December 21, 2025
Hosts: Skip Montreux, Dez Morgan, Samantha Vega

---

Overview

In this episode, hosts Skip and Dez provide an in-depth update on the rapidly evolving GLP-1 inhibitor market, focusing on pharmaceutical drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. The discussion covers the science behind these drugs, key market players, the differences between leading products, and a major recent acquisition in the industry. The episode also integrates relevant business English vocabulary and insightful commentary useful for professionals seeking to expand both their industry knowledge and language skills.

---

Key Discussion Points & Insights

1. What are GLP-1 Inhibitors? (01:35–05:03)

• Definition & Popularity:
  GLP-1 inhibitors are a class of drugs, such as Ozempic and Wegovy, that help with weight loss and, in some cases, treat type 2 diabetes.
• Active Ingredient:
  Both drugs contain Semaglutide, which mimics a hormone controlling blood sugar and appetite (02:30).
• Differentiation:
  • Ozempic: Developed for type 2 diabetes, sometimes prescribed "off label" for weight loss (02:50–03:20).
  • Wegovy: Specifically geared toward weight loss, with a higher dosage of Semaglutide for stronger appetite suppression (03:49–03:59).
• Quote:
  "Ozempic was originally developed to treat type 2 diabetes, whereas Wegovy is specifically geared for weight loss." — Skip (02:50)

---

2. Market Leaders: Novo Nordisk vs. Eli Lilly (05:03–08:23)

• Novo Nordisk:

  • Market leader with a 57% share attributed to Wegovy.
  • Strengths: First mover, more affordable pricing, variety in dosage form (injection vs. tablet) (04:32–04:40, 06:29–06:56, 07:45–08:06).

• Eli Lilly:

  • Entered market with Mounjaro (diabetes) and Zepbound (weight loss).
  • Mounjaro’s active ingredient, Tirzepatide, often proves more effective for weight loss than Semaglutide:
    "A major 18 month US study...those taking tirzepatide lost 20.2% of their body weight, compared to 13.7% lost by those taking Semaglutide." — Skip (05:50–06:13)

• Pricing and Side Effects:

  • Mounjaro tends to be more expensive and is only available as a weekly injection, while Wegovy offers a daily tablet option (06:29–08:06).
  • Wegovy tends to have slightly more frequent/intense side effects compared to Mounjaro (07:18–07:42).

• Summary:
  "So the conundrum for consumers is choosing between price and convenience versus the potential for greater weight loss." — Dez (08:06–08:15)

---

3. Major Industry Move: Pfizer’s Acquisition of Metsera (08:23–12:42)

• Details of the Deal:
  • Pfizer acquired Metsera, a Californian biopharma startup, for up to $10 billion, with part of the payment dependent on FDA approval of Metsera’s drugs (08:38–09:20).
  • A last-minute bid by Novo Nordisk attempted to acquire Metsera for $9 billion, but was ultimately withdrawn due to antitrust concerns (10:00–12:08).
• Strategic Value:
  • Metsera is developing a monthly-injection GLP-1 drug (MET097I), offering greater convenience (requiring only one injection per month).
  • Another Metsera drug, an “amylin analog,” could potentially offer increased weight loss when combined with GLP-1 therapies (10:42–11:36).
• Regulatory & Legal Issues:
  • Novo Nordisk withdrew its bid due to US regulator antitrust warnings; Pfizer even filed a lawsuit claiming Novo Nordisk’s bid was anti-competitive (12:12–12:29).
  • "Novo Nordisk's board...decided to withdraw their offer after US regulators warned that their acquisition would raise antitrust concerns." — Skip (11:52–12:08)
• Market Impact:
  • Pfizer, as a new entrant, now poses a potential challenge to the existing market leaders.
  • "The extremely lucrative weight loss market suddenly has a new player in town." — Skip (12:35–12:42)

---

4. Business English Vocabulary (13:20–16:42)

• Acquisition:
  Explained as when one company buys another.
  "Pfizer's acquisition of Metsera and why they bought the company to enter the GLP1 market." — Skip (13:31)
• Go to the trouble of:
  Means to make a special effort to do something, even if it’s not strictly necessary.
  "...why Novo Nordisk would go to the trouble of marketing two brands, Ozempic and Wegovy, when they are based on very similar drugs.” — Dez (15:05)
• Competitive Advantage:
  A quality that makes a company more successful than rivals, e.g., pricing, technology, branding.
  "Ozempic's lower price gave Novo Nordisk a competitive advantage over Eli Lilly's products in many markets.” — Skip (16:08)

---

Notable Quotes & Memorable Moments

• "A major 18 month US study...those taking tirzepatide lost 20.2% of their body weight, compared to 13.7%...with Semaglutide." — Skip (05:50–06:13)
• "At the 11th hour, a competitor put in a counterbid of $9 billion...Guess who that bidder was?" — Skip (09:36–09:50)
• "This deal could be a major coup for Pfizer." — Dez (11:36–11:43)
• "If those two drugs do indeed work well together, this deal could be a major coup for Pfizer." — Dez (11:36)

---

Key Timestamps

• [01:35–05:03] – GLP-1 overview, product differentiation (Ozempic vs. Wegovy)
• [05:03–08:23] – Market share battle: Novo Nordisk vs. Eli Lilly
• [08:23–12:42] – Pfizer’s acquisition of Metsera and consequences for the market
• [13:20–16:42] – Business English vocabulary explanations

---

Episode Conclusion

Skip and Dez wrap up by emphasizing the ongoing competition in the GLP-1 market, the impact of Pfizer’s big move, and the vocabulary lessons embedded in the episode. They invite listeners to access bonus content focusing on additional vocabulary and remind them of the show's value for business English learners.

---

This summary provides a comprehensive look at industry trends, competitive strategy, and language learning, staying true to the tone and instructional focus of the podcast.

Transcript

[A]

From Tokyo, Japan and Changsha, China, this is down to business English with your hosts, Skip Montreux and Des Morgan.

[B]

Skip, do my eyes deceive me?

[C]

What are you talking about?

[B]

Des, if I'm not mistaken, it looks like you've lost a bit of weight.

[C]

You're not the first person to notice that. Deserve. As a matter of fact, yes, I have dropped a few kilograms over the past month or so.

[B]

How did you manage that? You're not taking one of those weight loss drugs, are you?

[C]

You mean a GLP1 inhibitor drug like Ozempic or Wegavy?

[B]

Yeah, that was the type of drug I was referring to.

[C]

No, nothing like that. I've just been eating better and trying to get a bit more exercise.

[B]

Well done. Keep it up.

[C]

I'll do my best. But it's funny you brought up those drugs.

[B]

Didn't we report on them a while back?

[C]

Yes, we did. As a matter of fact, over 100 episodes ago in D2B289. And interestingly enough, GLP1 drugs happen to be the focus of my report today.

[B]

Are you going to give us an update on the weight loss drug market then?

[C]

That's part of it. But I also want to report on a recent acquisition that will definitely shake up the market.

[B]

Sounds interesting.

[C]

So let's do it. Let's get D2B down to business with the GLP1 inhibitors. Who are the big players? What products do they make? And who has just entered this lucrative market?

[B]

Anyone who's familiar with the weight loss drug market, or indeed who listened to D2B289 back in December 2023 will know that the biggest player in this sector is the Danish pharmaceutical company Novo Nordisk. And they have two different drugs on the market. Ozempic and Wegovy.

[C]

Those are the two top selling weight loss products out there. Yes.

[B]

Remind me, what's the difference between Ozemp and Wegovy?

[C]

Good question, as they are very similar. Both include the active ingredient Semaglutide, which is a synthetic version of a hormone our bodies naturally produce to control blood sugar levels and suppress our appetite.

[B]

So why two drugs?

[C]

Ozempic was originally developed to treat type 2 diabetes, whereas WeGovy is specifically geared for weight loss.

[B]

Ah, now I remember. But if memory serves me, Ozempic is also prescribed off label for weight loss, not just for diabetes.

[C]

That's right. And by off label you are referring to the practice of prescribing a drug for a purpose different to the one it was approved to treat.

[B]

That's what I mean? Yes. So in this case, Ozempic is being prescribed to treat weight loss, although it's not the primary purpose it was approved for.

[C]

Exactly. It was approved to treat type 2 diabetes. Weight loss was a secondary benefit, but of course Novo Nordisk has Wegavy for that purpose.

[B]

Why the two different products? If they're basically the same drug, why go to all the trouble of marketing two brands?

[C]

Another excellent question. Does it comes down to dosage and intended use?

[B]

Dosage meaning the amount a patient takes?

[C]

Yes. As Ozempic was developed to treat diabetes, the dosage is calibrated to control blood sugar levels. Wegovy, on the other hand, is designed for weight management and uses a higher dose of Semaglutide and achieves stronger appetite suppression effects.

[B]

Got it. Yeah, that makes sense.

[C]

In any case, Novo Nordisk is without a doubt the market leader in the overweight or obesity market.

[B]

With two products out there, they should be.

[C]

According to Novo Nordisk's 2024 annual report, WeGovy has a 57% market share.

[B]

Oh, that's substantial. Shareholders must be pretty happy with that.

[C]

But there is a new glp, one kid on the block that is quickly eroding Wegavi's position, especially in North America.

[B]

Really? Now who would that be?

[C]

That would be Eli Lilly's weight loss products, Mounjaro and Zepbound.

[B]

Eli Lilly is marketing two distinct products as well?

[C]

Yes. Mongero is the diabetes drug and Zepbound is the weight loss medication. And since entering the market in 2022, Mounjaro has been making inroads into the and taking a progressively larger share.

[B]

Why is that? Is it a better pharmaceutical?

[C]

It's all a bit technical, but the clinical trials have shown that the active ingredient in Mongero, Tirzepatide, is generally more effective for weight loss than Semaglutide, the

[B]

active ingredient in Wegovia and Ozempic.

[C]

That's right.

[B]

So people who take Mounjaro lose more weight than those taking Ozempic?

[C]

It seems that way. A major 18 month US study of 751 obese or overweight patients found that those taking tirzepatide lost 20.2% of their body weight, compared to 13.7% lost by those taking Semaglutide.

[B]

That is quite a bit more effective. No wonder Manjaro is eating into Wegovy's market share.

[C]

Well, Novo Nordisk products are still the market leader and they have a couple things working in their favor.

[B]

Like what?

[C]

One factor is pricing. In most markets Monjaro tends to be more expensive by very much. It varies depending on the country and insurance coverage, so it's a little difficult to quote exact numbers. But overall, Ozempic is generally the more affordable of the two, which gives Novo Nordisk a competitive advantage that certainly works

[B]

in Novo Nordisk's favor.

[C]

Also, that clinical trial I mentioned was done with the maximum dosage of both drugs. The maximum dose of Mongero is considerably higher than that recommended for Wegovy.

[B]

And that adds to the price again.

[C]

And it could be a reason for the increased weight loss results.

[B]

And how about side effects? Does one brand have milder side effects than the other?

[C]

It's always hard to make broad statements because people respond differently to medications. However, clinical data does suggest that Wegovy is associated with slightly more frequent or more intense side effects compared to Monjaro.

[B]

So that would be a point in Mounjaro's favorite.

[C]

Possibly, yes. But there is another factor to consider. At the moment, Mounjaro is only available as a weekly injection, but if you take Wegovy, you have a choice between giving yourself a weekly injection or taking a more convenient daily tablet.

[B]

So the conundrum for consumers is choosing between price and convenience versus the potential for greater weight loss.

[C]

Well, many people do very well on Wegovy, but based on current studies, that is an accurate summary.

[B]

So that's the current market. And those are the two heavyweights. Novo Nordisk and Eli Lilly. You said something about another company recently entering the market.

[C]

I did.

[B]

What's that about?

[C]

In early November this year, Pfizer finalized a deal to buy the Californian biopharma startup Metsera for a purchase price of up to $10 billion.

[B]

Up to. What does that mean? They haven't settled on the final price.

[C]

The deal is structured like this. Pfizer has offered to pay $65.60 per share, with an additional $20.65 per share contingent on Metsera's drugs passing certain FDA tests. If Metcera passes all the tests, the deal will amount to around $10 billion.

[B]

That does sound like a lot of money.

[C]

Yes, it does. In late September, both companies actually had agreed to own a valuation of up to $7.3 billion.

[B]

I'm confused. Why would Pfizer up its offer?

[C]

Well, this is where the story gets very interesting. At the 11th hour, a competitor put in a counterbid of $9 billion, pushing the price up. Guess who that bidder was?

[B]

I would say then it must be either Eli Lilly or Novo Nordisk.

[C]

Yeah, but which one?

[B]

I'm Gonna go with Novo, am I right?

[C]

Well, guess. Des, you are 100% correct.

[B]

But I don't get it. If Novo Nordisk already has successful GLP1 drugs in the market, why would they want to buy Metcera?

[C]

This is a little technical as well, but I'll give it a go. Mtsera's GLP1 receptor agonist, currently known by the codename of MET097I, is much longer lasting than other GLP1 drugs. The bottom line is it only requires one injection a month.

[B]

Once a month. That's way better than the weekly injections.

[C]

Mitcera also has a second Drug in Development, MET233I, which is an AML analog. Early studies suggest that when it's combined with a GLP1 receptor agonist, patients may achieve even greater weight loss than with either drug alone.

[B]

Well, you're right, that was pretty technical. But I do follow you. What exactly, though, is an Amlin analog?

[C]

Amlin is a hormone released by the pancreas. It helps you feel full and slows down how quickly food leaves your stomach.

[B]

In other words, it makes you forget about food. Yeah, I got it. So what you're saying is by taking the two drugs together, people feel full even quicker?

[C]

That is the bottom line, yes.

[B]

If those two drugs do indeed work well together, this deal could be a major coup for Pfizer.

[C]

And it seems Novo Nordisk was well aware of that. So they put in a bid of their own.

[B]

And why didn't Metsehra accept that bid?

[C]

In the end, Novo Nordisk's board of directors decided to withdraw their offer after US Regulators warned that their acquisition would raise antitrust concerns.

[B]

So they didn't want to risk a long, expensive legal battle.

[C]

Then, on top of that, Pfizer actually filed a lawsuit against Novo Nordisk. They claimed Novo's counterbid was an illegal attempt to block a potential competitor from entering the market.

[B]

I would have to say they kind of had a point there.

[C]

In any case, Novo's offer didn't go through and Pfizer successfully acquired Nova Met

[B]

Sarah, and the extremely lucrative weight loss market suddenly has a new player in town.

[C]

That it does. And on that note, I think it is time for us to get D2V down to vocabulary. Alright, let's kick off today's down to Vocabulary with our first word, acquisition. An acquisition is the process of getting something in business. An acquisition is when one company buys another company, or a large part of it.

[B]

You'll hear this term a lot in the business news, especially when companies want to grow quickly. Enter a new market or gain new technology or expertise.

[C]

One of the main topics in today's episode was Pfizer's acquisition of Metsera and why they bought the company to enter the GLP1 market.

[B]

You also explained how Novo Nordisk's board of directors decided to withdraw their offer for Metsera after US Regulators warned that the acquisition would raise antitrust concerns.

[C]

In simpler terms, Novo Nordisk decided not to buy MTSERA because it would probably cause them a lot of legal issues. Can you give us another example using acquisition devs?

[A]

Sure.

[B]

I'll give you a very recent example using the verb form of acquisition. Earlier this month there was some huge news in the media industry when Netflix announced they had acquired or Warner Brothers Discovery.

[C]

Yes, that is big news. We will need to do an episode on that sometime.

[B]

I agree. I'll look into that. The next word on our list is the expression go to the trouble of when you go to the trouble of doing something, you make a special effort to do it, especially when it takes time, money or extra work.

[C]

This expression suggests that the action isn't strictly necessary. So the speaker is asking why someone would bother doing it, or they are wondering why they are doing it.

[B]

In the report, I used this expression when I asked Skip why Novo Nordisk would go to the trouble of marketing two brands, Ozempic and WeGovy, when they are based on very similar drugs. In other words, I was asking why the company would make the extra effort to manage two products instead of just one.

[C]

Here's a question you might hear in a B2B meeting. Someone may ask why go to the trouble of developing the system in house when we can outsource it to a specialist provider?

[B]

That question comes up all the time in business.

[C]

The final item on our DTV list today is the a competitive advantage. A competitive advantage is something that makes a company more successful than its competitors.

[B]

It could be lower prices, better technology, stronger branding, or even more convenient services.

[C]

In the episode, I said that Ozempic's lower price gave Novo Nordisk a competitive advantage over Eli Lilly's products in many markets.

[B]

But simply, Novo Nordisk can compete more effectively because its product is often more affordable for its patients.

[C]

I think that is one of the biggest challenges facing any business, developing a strong competitive advantage over rivals.

[A]

Would you like to help down to Business English Reach more people wanting to improve their business English skills? Follow down to Business English on Apple Podcasts, YouTube, Music, Spotify or any place podcasts are found. Leave a rating and a review and tell everyone how much you Enjoy the show.

[B]

Thank you very much for that report on all the recent developments in the GLP1 market skip.

[C]

You are more than welcome, Des. I hope you and our listeners found it informative.

[B]

It will be interesting to see what Pfizer's impact will be on Novo Nordisk's market share.

[C]

It will DTB Members and Apple Podcast Subscribers the Bonus down to Vocabulary episode for today's report will be released very soon.

[B]

In that bonus episode, we will be discussing five additional vocabulary items that we used in today's report.

[C]

Those words and phrases to gear up for something to calibrate, to make inroads, to work in one's Favor and the 11th Hour D2B members be sure that

[B]

you have copied the Members Only Podcast Feed URL from your account page on the D2B website and have pasted it into the podcast app of your choice. That way you won't miss the bonus

[C]

D2B episode and Apple Podcast subscribers. You don't need to do anything. The bonus D2B episode will appear automatically in your podcast feed once it is released.

[B]

And if you're not yet a D2B member or an Apple Podcast subscriber, but find down to Business English helpful for your Business English studies, do consider supporting

[C]

the show as a member. You will gain access to all our Bonus Vocabulary Episodes, Members Only episodes, our interactive audio scripts, along with the complete library of our PDF scripts.

[B]

To become a D2B member, just visit d2benglish.com membership and sign up today.

[C]

That's D the number two benglish.com forward/membership. Thanks for listening everyone. See you next time. Bye bye.

[A]

Have a comment or question about today's show? Don't be shy. Visit the D2B website or Facebook page and post any comments or questions there. Skip DEZ or Samantha will be sure to leave a reply. Down to Business English Business News to improve your Business English.